FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010583755> ?p ?o ?g. }

• W3010583755 abstract "Innovative post-remission therapies are needed to eliminate residual AML cells. DC vaccination is a promising strategy to induce anti-leukaemic immune responses.We conducted a first-in-human phase I study using TLR7/8-matured DCs transfected with RNA encoding the two AML-associated antigens WT1 and PRAME as well as CMVpp65. AML patients in CR at high risk of relapse were vaccinated 10× over 26 weeks.Despite heavy pretreatment, DCs of sufficient number and quality were generated from a single leukapheresis in 11/12 cases, and 10 patients were vaccinated. Administration was safe and resulted in local inflammatory responses with dense T-cell infiltration. In peripheral blood, increased antigen-specific CD8+ T cells were seen for WT1 (2/10), PRAME (4/10) and CMVpp65 (9/10). For CMVpp65, increased CD4+ T cells were detected in 4/7 patients, and an antibody response was induced in 3/7 initially seronegative patients. Median OS was not reached after 1057 days; median RFS was 1084 days. A positive correlation was observed between clinical benefit and younger age as well as mounting of antigen-specific immune responses.Administration of TLR7/8-matured DCs to AML patients in CR at high risk of relapse was feasible and safe and resulted in induction of antigen-specific immune responses. Clinical benefit appeared to occur more likely in patients <65 and in patients mounting an immune response. Our observations need to be validated in a larger patient cohort. We hypothesise that TLR7/8 DC vaccination strategies should be combined with hypomethylating agents or checkpoint inhibition to augment immune responses.The study was registered at https://clinicaltrials.gov on 17 October 2012 (NCT01734304) and at https://www.clinicaltrialsregister.eu (EudraCT-Number 2010-022446-24) on 10 October 2013." @default.
• W3010583755 created "2020-03-13" @default.
• W3010583755 creator A5003069482 @default.
• W3010583755 creator A5004138391 @default.
• W3010583755 creator A5009178208 @default.
• W3010583755 creator A5009874210 @default.
• W3010583755 creator A5011768650 @default.
• W3010583755 creator A5012020159 @default.
• W3010583755 creator A5016143999 @default.
• W3010583755 creator A5033250378 @default.
• W3010583755 creator A5033935778 @default.
• W3010583755 creator A5042295492 @default.
• W3010583755 creator A5054194986 @default.
• W3010583755 creator A5054447908 @default.
• W3010583755 creator A5055470051 @default.
• W3010583755 creator A5059567988 @default.
• W3010583755 creator A5063176873 @default.
• W3010583755 creator A5066818291 @default.
• W3010583755 creator A5067305238 @default.
• W3010583755 creator A5069712978 @default.
• W3010583755 creator A5086659894 @default.
• W3010583755 creator A5086730170 @default.
• W3010583755 creator A5089965167 @default.
• W3010583755 creator A5068979347 @default.
• W3010583755 date "2020-01-01" @default.
• W3010583755 modified "2023-10-02" @default.
• W3010583755 title "Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial" @default.
• W3010583755 cites W1763981524 @default.
• W3010583755 cites W1971212779 @default.
• W3010583755 cites W2004037261 @default.
• W3010583755 cites W2010109838 @default.
• W3010583755 cites W2038466229 @default.
• W3010583755 cites W2040602022 @default.
• W3010583755 cites W2044131792 @default.
• W3010583755 cites W2075709249 @default.
• W3010583755 cites W2076997401 @default.
• W3010583755 cites W2087665046 @default.
• W3010583755 cites W2115855421 @default.
• W3010583755 cites W2116858301 @default.
• W3010583755 cites W2126594957 @default.
• W3010583755 cites W2162578269 @default.
• W3010583755 cites W2164971085 @default.
• W3010583755 cites W2171236933 @default.
• W3010583755 cites W2300461615 @default.
• W3010583755 cites W2519109143 @default.
• W3010583755 cites W2560536699 @default.
• W3010583755 cites W2594967879 @default.
• W3010583755 cites W2606935378 @default.
• W3010583755 cites W2625759860 @default.
• W3010583755 cites W2633117067 @default.
• W3010583755 cites W2738658820 @default.
• W3010583755 cites W2747973325 @default.
• W3010583755 cites W2758263899 @default.
• W3010583755 cites W2781525129 @default.
• W3010583755 cites W2784179963 @default.
• W3010583755 cites W2788672255 @default.
• W3010583755 cites W2789910920 @default.
• W3010583755 cites W2900410545 @default.
• W3010583755 doi "https://doi.org/10.1002/cti2.1117" @default.
• W3010583755 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7053229" @default.
• W3010583755 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32153780" @default.
• W3010583755 hasPublicationYear "2020" @default.
• W3010583755 type Work @default.
• W3010583755 sameAs 3010583755 @default.
• W3010583755 citedByCount "17" @default.
• W3010583755 countsByYear W30105837552021 @default.
• W3010583755 countsByYear W30105837552022 @default.
• W3010583755 countsByYear W30105837552023 @default.
• W3010583755 crossrefType "journal-article" @default.
• W3010583755 hasAuthorship W3010583755A5003069482 @default.
• W3010583755 hasAuthorship W3010583755A5004138391 @default.
• W3010583755 hasAuthorship W3010583755A5009178208 @default.
• W3010583755 hasAuthorship W3010583755A5009874210 @default.
• W3010583755 hasAuthorship W3010583755A5011768650 @default.
• W3010583755 hasAuthorship W3010583755A5012020159 @default.
• W3010583755 hasAuthorship W3010583755A5016143999 @default.
• W3010583755 hasAuthorship W3010583755A5033250378 @default.
• W3010583755 hasAuthorship W3010583755A5033935778 @default.
• W3010583755 hasAuthorship W3010583755A5042295492 @default.
• W3010583755 hasAuthorship W3010583755A5054194986 @default.
• W3010583755 hasAuthorship W3010583755A5054447908 @default.
• W3010583755 hasAuthorship W3010583755A5055470051 @default.
• W3010583755 hasAuthorship W3010583755A5059567988 @default.
• W3010583755 hasAuthorship W3010583755A5063176873 @default.
• W3010583755 hasAuthorship W3010583755A5066818291 @default.
• W3010583755 hasAuthorship W3010583755A5067305238 @default.
• W3010583755 hasAuthorship W3010583755A5068979347 @default.
• W3010583755 hasAuthorship W3010583755A5069712978 @default.
• W3010583755 hasAuthorship W3010583755A5086659894 @default.
• W3010583755 hasAuthorship W3010583755A5086730170 @default.
• W3010583755 hasAuthorship W3010583755A5089965167 @default.
• W3010583755 hasBestOaLocation W30105837551 @default.
• W3010583755 hasConcept C10205521 @default.
• W3010583755 hasConcept C104317684 @default.
• W3010583755 hasConcept C126322002 @default.
• W3010583755 hasConcept C147483822 @default.
• W3010583755 hasConcept C150194340 @default.
• W3010583755 hasConcept C167672396 @default.
• W3010583755 hasConcept C190727270 @default.
• W3010583755 hasConcept C203014093 @default.

• next